Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects

被引：0
|
作者：
Imondi, AR [1 ]
机构：
[1] Battelle Mem Inst, Columbus, OH 43201 USA
来源：
SEMINARS IN ONCOLOGY | 1998年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22 / 30
页数：9
相关论文
共 50 条
  • [1] Effects of dexrazoxane and amifostine on evolution of doxorubicin cardiomyopathy in vivo
    Bjelogrlic, Snezana K.
    Radic, Jelena
    Radulovic, Sinisa
    Jokanovic, Milan
    Jovic, Viktor
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2007, 232 (11) : 1414 - 1424
  • [2] Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
    Kissel, Maria
    Berndt, Sandra
    Fiebig, Lukas
    Kling, Simon
    Ji, Qunsheng
    Gu, Qingyang
    Lang, Tina
    Hafner, Frank-Thorsten
    Teufel, Michael
    Zopf, Dieter
    ONCOTARGET, 2017, 8 (63): : 107096 - 107108
  • [3] Dexrazoxane for protection against cardiotoxic effects of anthracyclines
    Sehested, M
    Holm, B
    Jensen, PB
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2884 - 2884
  • [4] PROTECTIVE EFFECTS OF DEXRAZOXANE ON DOXORUBICIN-INDUCED CARDIOTOXICITY.
    Mody, H.
    Vaidya, T.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S15 - S15
  • [5] PROTECTIVE EFFECTS OF DEXRAZOXANE ON DOXORUBICIN-INDUCED CARDIOTOXICITY.
    Mody, H.
    Vaidya, T.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S107 - S107
  • [6] Topoisomerase IIα-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin
    Yan, Tiandong
    Deng, Shiwei
    Metzger, Annegret
    Goedtel-Armbrust, Ute
    Porter, Andrew C. G.
    Wojnowski, Leszek
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (05) : 1075 - 1085
  • [7] Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children
    Lipshultz, SE
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 328 - 331
  • [8] The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS)
    Kopp, Lisa M.
    Bernstein, Mark L.
    Schwartz, Cindy L.
    Ebb, David
    Krailo, Mark D.
    Grier, Holcombe E.
    Meyers, Paul A.
    Wexler, Leonard H.
    Marina, Neyssa
    Womer, Richard
    Janeway, Katherine A.
    Gorlick, Richard Greg
    Lipshultz, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Antitumor effects of bisphosphonates: Promising preclinical evidence
    Guise, Theresa A.
    CANCER TREATMENT REVIEWS, 2008, 34 : S19 - S24
  • [10] Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study
    Yang QuanJun
    Yang GenJin
    Wan LiLi
    Han YongLong
    Huo Yan
    Li Jie
    Huang JinLu
    Lu Jin
    Gan Run
    Guo Cheng
    PLOS ONE, 2017, 12 (01):
12345